JANTZ DEREK
Known title: Chief Scientific OfficerCIK: 0001769828
Associated companies
Transaction History
| DTIL | ▼ Sell | Open Market | 18,849 | $39K | 6/8/2022 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 29,545 | — | 6/7/2022 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 12,199 | — | 6/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.